摘要
芳香化酶抑制剂在解救和辅助治疗乳腺癌方面,均显示出不逊于三苯氧胺的临床疗效,该类药物毒性反应成为人们关注的主要问题。近期资料显示芳香化酶抑制剂对血管、子宫的毒副作用明显少于三苯氧胺,而对血脂、骨丢失的影响较三苯氧胺明显,但该类药物的治疗相关毒性多为轻中度,均可很好处理。由于芳香化酶抑制剂应用时间尚短,其远期毒性还需进一步临床评价。
Aromatase Inhibitors （AIs） are at least equivalent to or more effective than tamoxifen in the adjuvant or salvage treatment for postmenopausal patients with hormone receptor-positive breast cancer,side effects of Als have become another major concern. Recent data have shown AIs have less vascular and uterine adverse evevts than tamoxifen,but some concern exists regarding their effect on lipid metabolism and bone turnover, and the side effects related to AIs are usually mild to moderate in severity, and rarely severe enough to require discontinuation of treatment.Because of shorter follow up period,the distant side effect of AIs needs to be evaluated.
出处
《中国药物警戒》
2006年第2期68-71,共4页
Chinese Journal of Pharmacovigilance
